2U8

Mavoglurant

Created:	2014-02-05
Last modified:	2021-03-13

Find Related PDB Entry
1 entries where 2U8 is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	46
Chiral Atom Count	3
Bond Count	48
Aromatic Bond Count	6

2D diagram of 2U8

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Mavoglurant
Synonyms	methyl (3aR,4S,7aR)-4-hydroxy-4-[(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate
Systematic Name (OpenEye OEToolkits)	methyl (3aR,4S,7aR)-4-[2-(3-methylphenyl)ethynyl]-4-oxidanyl-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
Formula	C₁₉ H₂₃ N O₃
Molecular Weight	313.391
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=C(OC)N3C2CCCC(O)(C#Cc1cccc(c1)C)C2CC3
SMILES	CACTVS	3.385	COC(=O)N1CC[CH]2[CH]1CCC[C]2(O)C#Cc3cccc(C)c3
SMILES	OpenEye OEToolkits	1.7.6	Cc1cccc(c1)C#CC2(CCCC3C2CCN3C(=O)OC)O
Canonical SMILES	CACTVS	3.385	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc3cccc(C)c3
Canonical SMILES	OpenEye OEToolkits	1.7.6	Cc1cccc(c1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
InChI	InChI	1.03	InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
InChIKey	InChI	1.03	ZFPZEYHRWGMJCV-ZHALLVOQSA-N

Drug Info: DrugBank

DrugBank ID	DB13004
Name	Mavoglurant
Groups	investigational
Description	Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Synonyms	Mavoglurant
Categories	Heterocyclic Compounds, Fused-Ring
CAS number	543906-09-8

Related Resource References

Resource Name	Reference
Pharos	CHEMBL3087515
PubChem	9926832
ChEMBL	CHEMBL3087515

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.